Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Miyake

Showing results (81-90 of 555) with videos related to

Pageof 56
Sort By:
Expert Opinion on Investigational Drugs|April 26, 2006
The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancerHideaki Miyake, Isao Hara, Masato Fujisawa, et al.
Clinical Genitourinary Cancer|September 19, 2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell CarcinomaHideaki Miyake, Satoshi Imai, Ken-Ichi Harada, et al.
Urology|November 30, 2014
Objective assessment of residual nerve tissues in radical prostatectomy specimens by immunohistochemical staining of neuronal nitric oxide synthase-positive nerves and its impact on postoperative erectile functionHideaki Miyake, Hosny M Behnsawy, Nobuyuki Hinata, et al.
Urologic Oncology|January 26, 2015
Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladderMasatomo Nishikawa, Hideaki Miyake, Hosny M Behnsawy, et al.
Urologic Oncology|November 19, 2013
Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomyMasatomo Nishikawa, Hideaki Miyake, Ken-ichi Harada, et al.
Expert Review of Anticancer Therapy|December 13, 2005
Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospectsHideaki Miyake, Isao Hara, Masato Fujisaw, et al.
International Journal of Clinical Oncology|September 11, 2013
Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in JapanHideaki Miyake, Ken-Ichi Harada, Masafumi Kumano, et al.
Current Urology|June 12, 2014
Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladderKen-Ichi Harada, Hideaki Miyake, Tomoaki Terakawa, et al.
Urologic Oncology|January 29, 2014
Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomyHiromoto Tei, Hideaki Miyake, Ken-ichi Harada, et al.
Clinical Genitourinary Cancer|July 31, 2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Pageof 56

Showing results (81-90 of 555) with videos related to

Sort By:
Pageof 56
Expert Opinion on Investigational Drugs|April 26, 2006
The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancerHideaki Miyake, Isao Hara, Masato Fujisawa, et al.
Clinical Genitourinary Cancer|September 19, 2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell CarcinomaHideaki Miyake, Satoshi Imai, Ken-Ichi Harada, et al.
Urology|November 30, 2014
Objective assessment of residual nerve tissues in radical prostatectomy specimens by immunohistochemical staining of neuronal nitric oxide synthase-positive nerves and its impact on postoperative erectile functionHideaki Miyake, Hosny M Behnsawy, Nobuyuki Hinata, et al.
Urologic Oncology|January 26, 2015
Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladderMasatomo Nishikawa, Hideaki Miyake, Hosny M Behnsawy, et al.
Urologic Oncology|November 19, 2013
Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomyMasatomo Nishikawa, Hideaki Miyake, Ken-ichi Harada, et al.
Expert Review of Anticancer Therapy|December 13, 2005
Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospectsHideaki Miyake, Isao Hara, Masato Fujisaw, et al.
International Journal of Clinical Oncology|September 11, 2013
Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in JapanHideaki Miyake, Ken-Ichi Harada, Masafumi Kumano, et al.
Current Urology|June 12, 2014
Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladderKen-Ichi Harada, Hideaki Miyake, Tomoaki Terakawa, et al.
Urologic Oncology|January 29, 2014
Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomyHiromoto Tei, Hideaki Miyake, Ken-ichi Harada, et al.
Clinical Genitourinary Cancer|July 31, 2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Pageof 56